SG11202004172UA - Il2rbeta/common gamma chain antibodies - Google Patents

Il2rbeta/common gamma chain antibodies

Info

Publication number
SG11202004172UA
SG11202004172UA SG11202004172UA SG11202004172UA SG11202004172UA SG 11202004172U A SG11202004172U A SG 11202004172UA SG 11202004172U A SG11202004172U A SG 11202004172UA SG 11202004172U A SG11202004172U A SG 11202004172UA SG 11202004172U A SG11202004172U A SG 11202004172UA
Authority
SG
Singapore
Prior art keywords
il2rbeta
chain antibodies
gamma chain
common gamma
common
Prior art date
Application number
SG11202004172UA
Other languages
English (en)
Inventor
Peter Brauer
John Connolly
Richard Hopkins
Junyun Lai
Jianrong Lionel Low
Kar Wai Tan
Cheng-I Wang
Siok Ping Yeo
Original Assignee
Agency Science Tech & Res
Euchloe Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Euchloe Bio Pte Ltd filed Critical Agency Science Tech & Res
Publication of SG11202004172UA publication Critical patent/SG11202004172UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202004172UA 2017-11-10 2018-11-09 Il2rbeta/common gamma chain antibodies SG11202004172UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SG10201709289S 2017-11-10
US201862652501P 2018-04-04 2018-04-04
US201862735347P 2018-09-24 2018-09-24
PCT/EP2018/080765 WO2019092181A1 (en) 2017-11-10 2018-11-09 Il2rbeta/common gamma chain antibodies

Publications (1)

Publication Number Publication Date
SG11202004172UA true SG11202004172UA (en) 2020-06-29

Family

ID=64362498

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202004172UA SG11202004172UA (en) 2017-11-10 2018-11-09 Il2rbeta/common gamma chain antibodies

Country Status (7)

Country Link
US (3) US11739157B2 (zh)
EP (1) EP3707162A1 (zh)
JP (2) JP7269249B2 (zh)
CN (1) CN111954680B (zh)
SG (1) SG11202004172UA (zh)
TW (1) TWI800552B (zh)
WO (1) WO2019092181A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190367605A1 (en) * 2016-11-10 2019-12-05 Medimmune, Llc Binding Molecules Specific For ASCT2 And Uses Thereof
TW202031683A (zh) * 2018-11-09 2020-09-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
TW202039557A (zh) * 2018-11-09 2020-11-01 新加坡商優其洛伊生物私人有限公司 介白素2受體β(IL2Rβ)/共同γ鏈抗體
IL297225A (en) 2020-04-10 2022-12-01 Cytomx Therapeutics Inc Activatable cytokine constructs and related compositions and methods
TW202304958A (zh) 2021-03-16 2023-02-01 美商Ｃｙｔｏｍｘ生物製藥公司 經遮蔽之可活化之細胞介素構築體及相關之組成物及方法
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
CA3236138A1 (en) * 2021-11-02 2023-05-11 Shiyong GONG Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins
CN117700554A (zh) * 2023-08-03 2024-03-15 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种抗人源cd132的单克隆抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9705172A (es) 1995-01-09 1997-10-31 Boehringer Ingelheim Int Polipeptido asociado a il-2r y moleculas de adn que codifican el mismo.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2253942A1 (en) * 1996-05-10 1997-11-20 Biogen, Inc. Common gamma chain blocking agents
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
EP3444278A1 (en) 2013-02-26 2019-02-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
EP3212231B1 (en) 2014-10-27 2021-04-28 Agency For Science, Technology And Research Anti-tim-3 antibodies
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TR201901445T4 (tr) * 2015-08-06 2019-02-21 Agency Science Tech & Res Il2rbeta/yaygın gamma zinciri antikorları.
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies

Also Published As

Publication number Publication date
JP2021502116A (ja) 2021-01-28
US11739157B2 (en) 2023-08-29
TW201922785A (zh) 2019-06-16
TWI800552B (zh) 2023-05-01
CN111954680B (zh) 2024-03-15
EP3707162A1 (en) 2020-09-16
JP2023099051A (ja) 2023-07-11
US20220251221A1 (en) 2022-08-11
WO2019092181A1 (en) 2019-05-16
CN111954680A (zh) 2020-11-17
US20240026016A1 (en) 2024-01-25
US20240052046A1 (en) 2024-02-15
JP7269249B2 (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
HUE043421T2 (hu) IL-2R béta / közös gamma-lánc antitestek
IL268517A (en) Anti-tigit antibodies
IL269405A (en) Anti-SIRP-alpha antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL272227A (en) ANTI-TIGIT antibodies
IL267797B1 (en) Anti-gpc3 antibody
GB201709808D0 (en) Antibodies
SG11202004172UA (en) Il2rbeta/common gamma chain antibodies
IL273393A (en) New epsilon anti-CD3 antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
ZA202002141B (en) Anti-transthyretin antibodies
GB201720970D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
IL273529A (en) Anti-PACAP antibody
PT3348859T (pt) Correia
IL271067A (en) Anti-trkb antibodies
GB201711785D0 (en) Antibodies
GB201804346D0 (en) FHIR Chain
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies
GB201709592D0 (en) Antibody